We present evidence that treatment with NLRP3 and caspase1 inhibitors and IL-18 neutralization protects against allergen-induced EoE pathogenesis in a murine model of EoE, which provides evidence for an alternative treatment strategy to Th2 cytokine neutralization immunotherapy for EoE2,16,24. The gene discussed is NLRP3; the disease is eosinophilic esophagitis.